{"schema_version":"secwatch.filing_event.v1","accession":"0001736730-25-000068","form_type":"8-K","ticker":"CAMP","cik":"0001736730","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.839522+00:00","generated_at":"2026-05-17T13:18:49.928378+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CAMP4 reports Q2 net loss of $12.6M; cash $39.1M; pipeline advances in SYNGAP1 and UCD programs","bullets":["Net loss of $12.6M for Q2 2025, flat vs Q2 2024; R&D expenses $10.3M, G&A $4.2M.","Cash, cash equivalents and marketable securities $39.1M as of June 30, 2025, down from $49.3M on March 31, 2025.","SYNGAP1 program: translational data presented at ASGCT; GLP tox studies start Q3 2025; potential Phase 1/2 trial in H2 2026.","CMP-CPS-001 (UCD): completed dosing in MAD cohort 3; safety and biomarker data from SAD and MAD cohorts expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001736730-25-000068","json":"https://secwatch.observer/filing/0001736730-25-000068.json","markdown":"https://secwatch.observer/filing/0001736730-25-000068.md","text":"https://secwatch.observer/filing/0001736730-25-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000068/0001736730-25-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000068/camp-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:18:49.928378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}